(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

BEIZRAY

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

BEIZRAY

ST13

US500000098176852

Class

5

Filing

98176852

Registration

8274739

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

28

Latest update

05/26/2026

Trademark type

Word

Nice classes

5

Filing date

09/12/2023

Registration date

05/26/2026

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

05/26/2026

Last transaction

05/26/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

First use anywhere

10/15/2025

First use in commerce

10/15/2025

Drawing code

4

Owner type

99

Owner location

Zhuhai, Guangdong, CN

Examiner

KEATING, SHANNON B

Law office

O20

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Zhuhai Beihai Biotech Co., Ltd.

Representatives

Charles Ho Barron & Young PLLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Analgesics; Antiemetics; Biological preparations for the treatment of cancer; Blood substitute for human use; Chemical preparations for pharmaceutical or medical purposesfor the treatment of cancer; Chemical reagents for medical purposes; Medicinal infusions for treating cancer; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicines made of Chinese traditional medicinal herbs; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the treatment of cancer; Prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Publications

History of USPTO decisions and trademark events.

28 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

05/26/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

05/26/2026

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

05/05/2026

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

05/05/2026

DOCK

ASSIGNED TO EXAMINER

04/08/2026

SUPC

STATEMENT OF USE PROCESSING COMPLETE

04/07/2026

IUAF

USE AMENDMENT FILED

10/24/2025

EISU

TEAS STATEMENT OF USE RECEIVED

10/24/2025

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

06/27/2025

EX2G

SOU EXTENSION 2 GRANTED

06/27/2025

EXT2

SOU EXTENSION 2 FILED

06/27/2025

EEXT

SOU TEAS EXTENSION RECEIVED

06/27/2025

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

03/03/2025

EX1G

SOU EXTENSION 1 GRANTED

12/31/2024

EXT1

SOU EXTENSION 1 FILED

12/31/2024

EEXT

SOU TEAS EXTENSION RECEIVED

12/31/2024

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

07/02/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/07/2024

PUBO

PUBLISHED FOR OPPOSITION

05/07/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/17/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/01/2024

XAEC

EXAMINER'S AMENDMENT ENTERED

03/21/2024

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

03/21/2024

GNEA

EXAMINERS AMENDMENT E-MAILED

03/21/2024

CNEA

EXAMINERS AMENDMENT -WRITTEN

03/21/2024

DOCK

ASSIGNED TO EXAMINER

03/14/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

11/26/2023

NWAP

NEW APPLICATION ENTERED

09/13/2023

Continuous trademark protection

Get notified about every new filing that threatens BEIZRAY or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.